NCT06942611 Transcranial Electrical Stimulation for Treating Chronic Pain in Inflammatory Demyelinating Diseases
| NCT ID | NCT06942611 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-05-03 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-05-03 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Non-invasive neurostimulation can effectively improve patients' symptoms and has shown good therapeutic efficacy in alleviating the symptoms of IIDDs (Inflammatory Immune-mediated Demyelinating Diseases). However, some patients have not achieved the desired results, which may be due to individual differences in neural responsiveness . Therefore, this study aims to assess the therapeutic effect of transcranial electrical stimulation on improving symptoms such as painful spasm in IIDDs patients, by considering both the overall characteristics of IIDDs disease symptoms and individual differences in patients. The study will explore the imaging characteristics, electrophysiological features of the disease symptoms, and their relationship with clinical manifestations, while analyzing the key factors that influence treatment efficacy.
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with neuromyelitis optica spectrum disorder, multiple sclerosis, or other central nervous system inflammatory demyelinating diseases that meet the diagnostic criteria; Numeric Rating Scale (NRS) pain score ≥4; Age between 18 and 65 years, regardless of gender; Stable dose of immunosuppressive therapy for at least one month; EDSS score ≤6; Right-handed; Agree to participate and sign the informed consent form. Exclusion Criteria: A history of relapse within the past month; Recent medication adjustments or treatment with modified electroconvulsive therapy, transcranial magnetic stimulation, or other neurostimulation techniques within the past month; Participation in any other clinical trial within the past month or currently participating in another clinical trial; Presence of cochlear implants, pacemakers, or implanted stimulators in the brain; Skin integrity at the electrode placement site is compromised, or allergy to electrode gel or adhesive; A history of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections; Pregnant or breastfeeding women, or those planning to become pregnant in the near future; A score of ≥3 on item 3 (suicide item) of the HDRS-17, or a history of severe psychiatric disorders; Presence of severe or unstable organic diseases; Poor patient compliance preventing cooperation with treatment, follow-up, or clinical, EEG, and imaging data collection; Any other situation deemed unsuitable for participation in the study by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06942611 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06942611 currently recruiting?
Yes, NCT06942611 is actively recruiting participants. Contact the research team at haojunwei@vip.163.com for enrollment information.
Where is the NCT06942611 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06942611 clinical trial?
NCT06942611 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 80 participants.